Allergan has agreed to acquire Bonti, a Newport Beach, California-based clinical-stage biopharmaceutical company focused on developing and commercializing fast-acting neurotoxin programs for aesthetic and therapeutic applications.

Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase II development, EB-001A (aesthetic) and EB-001T (therapeutic).

The move adds to Allergan’s position in the area of medical aesthetics, which is supported by one of the company’s top-selling products, Botox (onabotulinumtoxinA), which had 2017 global sales of $3.16 billion.

Source: Allergan